Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that they and/or their parent(s) or legally acceptable representative(s) can and will comply with the requirements of the protocol.~* A male or female child aged between 3 and 8 years inclusive at the time of the first vaccination; children are eligible regardless of history of administration of influenza vaccine in a previous season. However, subjects who have received any seasonal or pandemic influenza vaccine within 6 months preceding the first dose of study vaccine will not be enrolled.~* Written informed consent obtained from the subject/from the parent(s)/legally acceptable representative(s) of the subject.~* Written assent obtained from the subject if/as required by local regulations.~* Subjects in stable health as determined by investigator's clinical examination and assessment of subjects' medical history.~* Access to a consistent means of telephone contact~Exclusion Criteria:~* Child in care.~* Use of an investigational or non-registered product other than the study vaccines within 30 days before study vaccination or planned use during study period. Routine registered childhood vaccinations are permitted.~* Prior receipt of any seasonal or pandemic influenza vaccine within 6 months preceding the first dose of study vaccine, or planned use of such vaccines during the study period. Prior receipt of more than one dose of a licensed hepatitis A vaccine, with the first dose administered at \>=12 months of age.~* Chronic administration of immunosuppressants or other immune-modifying drugs within 6 months prior to the first vaccine dose.~* Administration of immunoglobulins and/or any blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period.~* History of Guillain-Barre syndrome within 6 weeks of receipt of prior influenza virus vaccine.~* Any known or suspected allergy to any constituent of influenza vaccines ; a history of anaphylactic-type reaction to constituent of vaccine; or a history of severe adverse reaction to a previous influenza vaccine.~* Fever at the time of enrolment.~* Acute disease at the time of enrolment.~* Any significant disorder of coagulation or treatment with Coumadin derivatives or heparin.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.~* Ongoing aspirin therapy.~* Any other condition which, in the opinion of the Investigator, prevents the subject from participating in the study.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 8 Years
- Healthy Volunteers: t

Study Arms:
- FluLaval® Quadrivalent Group (Type: EXPERIMENTAL): Subjects between 3 and 8 years of age at the time of first vaccination received, if primed, 1 dose of FluLaval® Quadrivalent vaccine at Day 0 and, if unprimed, 2 doses of FluLaval® Quadrivalent vaccine at Days 0 and 28. The vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.
- Havrix Group (Type: ACTIVE_COMPARATOR): Subjects between 3 and 8 years of age at the time of first vaccination received, if primed, 1 dose of Havrix™ vaccine at Day 0 and, if unprimed, 2 doses of Havrix™ vaccine at Days 0 and 28. The vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).